PCVX reports Q1 2026 results after the close today, with one of the more committed short positions in mid-cap biotech setting the backdrop.
Short sellers hold roughly 10.8% of the free float — up 8.7% over the past month alone. That is not a position built casually. Days to cover have extended to nearly 12 days using FINRA's latest official count, meaning any forced covering would take time to absorb. The ORTEX short score has climbed to 61 and has risen every session this week, reflecting the building bearish conviction. Notably, borrow availability remains ample and cost to borrow is just 0.39% — bears are not paying a squeeze premium to hold this position, which suggests the short thesis is deliberate rather than opportunistic.
Options positioning adds a different texture. Puts dominate calls by more than two-to-one, with the put/call ratio at 2.27 — but that is actually slightly below its 20-day average of 2.29 and modestly below the recent trend, suggesting options traders have not materially added new defensive positioning heading into the print. The 52-week PCR range runs from 0.20 to 3.22, placing today's reading in the middle of the band. Technically, the RSI14 of 38.9 flags the stock as approaching oversold territory, and PCVX is down 2.2% over the past month despite a 2.6% bounce on Wednesday.
The bull-bear debate is fundamentally about timing and competitive moat. Bulls point to a $2.67B cash runway, VAX-31's Phase 3 data that they argue shows superiority over rivals, and ACIP's expansion of universal adult vaccination recommendations that widens the addressable market in the potential $10B+ pneumococcal vaccine space. The analyst consensus is firmly positive — eight buy ratings, no sells, and a mean price target around $104, implying roughly 87% upside from current levels. All recent analyst activity has been reiterations of buy ratings with modest target adjustments, signalling the Street hasn't turned. Bears counter that Vaxcyte has zero revenue, posted an estimated net loss of over $1.1B, and burns close to $750M in operating cash annually. Commercialisation is years away. Any setback in trial data, regulatory guidance, or CDC vaccination policy carries outsized downside for a pre-revenue name.
Institutional ownership reinforces the picture of a stock that serious long-only managers believe in. FMR (Fidelity) added roughly 1.8 million shares in the most recent reporting period, bringing its stake to 9.4%. T. Rowe Price added over 2.6 million shares to reach 8.7%. The insider picture is less instructive — recent sales by the COO and Principal Accounting Officer are small and appear routine, totalling well under $1M each.
At $57.10 — roughly 46% below the mean analyst target — the Q1 print is a test of whether the clinical and regulatory narrative still justifies a market cap near $8.5B for a company that will not be profitable for years.
See the live data behind this article on ORTEX.
Open PCVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
